| Date |
Title |
|
|
01/02/19
|
Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference
|
|
|
12/17/18
|
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
|
|
|
11/30/18
|
Statement by Richard Pops, Chairman and CEO of Alkermes on the Annual CDC Report on Drug Overdose Deaths and Suicide Mortality in the United States
|
|
|
11/29/18
|
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
|
|
|
11/06/18
|
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
|
|
|
11/06/18
|
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
|
|
|
11/01/18
|
Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
|
|
|
11/01/18
|
Trading in Alkermes Ordinary Shares Halted Today
|
|
|
10/29/18
|
Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
|
|
|
10/26/18
|
Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®
|
|
|
10/23/18
|
Alkermes Plc Reports Third Quarter 2018 Financial Results
|
|
|
10/17/18
|
Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress
|
|
|
10/16/18
|
Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results
|
|
|
09/10/18
|
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
|
|
|
09/05/18
|
Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
|
|
